Health
Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar ® Gel) for Persistently Active Systemic Lupus Erythematosus – DocWire News
Introduction: We assessed patient-reported outcomes from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin

Introduction: We assessed patient-reported outcomes from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection (RCI; Acthar® Gel) in patients with persistently active systemic lupus erythematosus (SLE) despite treatment with moderate-dose glucocorticoids.
Methods: The trial enrolled adults with active SLE and moderate-to-severe rash and/or arthritis despite use of stable glucocorticoids (7.5 mg/day to 30 mg/day prednisone equivalent), antimalarials,…
-
Business23 hours ago
Where will Berkshire Hathaway be in 1 year?
-
Noosa News18 hours ago
Two trapped and fighting for life after major three-vehicle crash in Brisbane
-
Business19 hours ago
Up 105% in a year, are Pro Medicus shares still a good buy today?
-
Business17 hours ago
Everything you need to know about the Coles dividend